Multistate models as a framework for estimand specification in clinical trials of complex processes

被引:8
|
作者
Buehler, Alexandra [1 ]
Cook, Richard J. [1 ]
Lawless, Jerald F. [1 ]
机构
[1] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
estimands; generalized transformation model; intercurrent events; robustness; semi-competing risks; QUALITY-ADJUSTED SURVIVAL; CAROTID-ENDARTERECTOMY; COMPETING RISKS; WIN-RATIO; POTENTIAL OUTCOMES; CAUSAL INFERENCE; BREAST-CANCER; OPEN-LABEL; REGRESSION; HAZARDS;
D O I
10.1002/sim.9675
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Intensity-based multistate models provide a useful framework for characterizing disease processes, the introduction of interventions, loss to followup, and other complications arising in the conduct of randomized trials studying complex life history processes. Within this framework we discuss the issues involved in the specification of estimands and show the limiting values of common estimators of marginal process features based on cumulative incidence function regression models. When intercurrent events arise we stress the need to carefully define the target estimand and the importance of avoiding targets of inference that are not interpretable in the real world. This has implications for analyses, but also the design of clinical trials where protocols may help in the interpretation of estimands based on marginal features.
引用
收藏
页码:1368 / 1397
页数:30
相关论文
共 50 条
  • [41] Digitization of Processes in clinical Trials
    Tripolt, Norbert
    Pferschy, Peter
    Kojzar, Harald
    Url, Jasmin
    Weber, Barbara
    Sourij, Caren
    Sourij, Harald
    WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 : 173 - 174
  • [42] Specification of phase Ⅰ of new drugs' clinical tolerance trials
    LI Guo-xin(Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
    沈阳药科大学学报, 2008, (S1) : 14 - 14
  • [43] Flexible multistate models for interval-censored data: Specification, estimation, and an application to ageing research
    Machado, Robson J. M.
    van den Hout, Ardo
    STATISTICS IN MEDICINE, 2018, 37 (10) : 1636 - 1649
  • [44] Specification of mixed logit models assisted by an optimization framework
    Paz, Alexander
    Arteaga, Cristian
    Cobos, Carlos
    JOURNAL OF CHOICE MODELLING, 2019, 30 : 50 - 60
  • [45] Shipping market models and the specification of freight rate processes
    Jostein Tvedt
    Maritime Economics & Logistics, 2003, 5 (4) : 327 - 346
  • [46] Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine-That is the Estimand
    van Eijk, Ruben P. A.
    Roes, Kit C. B.
    De Greef-van der Sandt, Inez
    van den Berg, Leonard H.
    Lu, Ying
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (04) : 817 - 825
  • [47] The role of the estimand framework in the analysis of patient-reported outcomes in single-arm trials: a case study in oncology
    Thomassen, Doranne
    Roychoudhury, Satrajit
    Amdal, Cecilie Delphin
    Reynders, Dries
    Musoro, Jammbe Z.
    Sauerbrei, Willi
    Goetghebeur, Els
    le Cessie, Saskia
    BMC MEDICAL RESEARCH METHODOLOGY, 2024, 24 (01)
  • [48] Bias, precision, and parameter redundancy in complex multistate models with unobservable states
    Bailey, Larissa L.
    Converse, Sarah J.
    Kendall, William L.
    ECOLOGY, 2010, 91 (06) : 1598 - 1604
  • [49] An estimand perspective on the Mixed-Model Repeated Measures (MMRM) for the analysis of longitudinal PRO data in clinical trials
    Skaltsa, Konstantina
    Floden, Libby
    Lawrance, Rachael
    QUALITY OF LIFE RESEARCH, 2021, 30 (SUPPL 1) : S26 - S27
  • [50] Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation
    Ionan, Alexei C.
    Paterniti, Miya
    Mehrotra, Devan, V
    Scott, John
    Ratitch, Bohdana
    Collins, Sylva
    Gomatam, Shanti
    Nie, Lei
    Rufibach, Kaspar
    Bretz, Frank
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (03): : 554 - 559